AZ shareholders want a deal

Share this article:

The AstraZeneca-Pfizer deal is not dead yet, even though AstraZeneca's declaration that it rejected Pfizer's so-called final bid makes it appear that Pfizer's attempt to take on the AstraZeneca pipeline, and a considerable tax benefit, is over.

The reason: final is not really final until May 26. UK rules allow Pfizer to raise its final bid if AstraZeneca recommends the existing bid, after which Pfizer can increase its offer.

The proposed deal has created a storm among AZ shareholders, with major owners AXA, Jupiter and Legal & General saying the British drugmaker should take the deal, while Bloomberg reports investor Neil Woodford says the company should stay independent. Bloomberg reports that Woodford, who used to run UK investment firm Invesco, says AZ's long-term outlook is strong. Woodford told Bloomberg that CEO Pascal Soriot has transformed the company's pipeline “from one of the poorest in the industry to arguably the best.”

Soriot laid out his case for independence earlier this month, noting that the company's prospects could lead AstraZeneca to earn more than $45 billion in sales by 2023. Some speculated at the time that the plea was more of an ask for more money that it was an effort to stay single.

Analysts have said $45 billion seems a little optimistic. Forbes contributor John LaMattina noted Wednesday that Soriot expects 19 experimental drugs to move into Phase III by the end of 2015, but says that this would be a feat for any company. He notes that Phase II is when most drugs drop out, and that AZ's Phase II-to-Phase-III transition rate is around 15%, lagging the industry's overall survival rate of around 29%.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Reimagining healthcare? We want to hear about it.
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters


More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.